Celadon Pharmaceuticals (LON:CEL) Shares Down 6.3% – Time to Sell?

Celadon Pharmaceuticals Plc (LON:CELGet Free Report)’s share price dropped 6.3% during mid-day trading on Friday . The stock traded as low as GBX 25 ($0.30) and last traded at GBX 30 ($0.37). Approximately 596,970 shares were traded during mid-day trading, an increase of 54% from the average daily volume of 386,756 shares. The stock had previously closed at GBX 32 ($0.39).

Celadon Pharmaceuticals Stock Performance

The firm has a market cap of £15.49 million, a price-to-earnings ratio of -281.25 and a beta of -0.26. The firm’s 50 day moving average price is GBX 17.69 and its 200-day moving average price is GBX 33.37. The company has a debt-to-equity ratio of 194.82, a current ratio of 1.92 and a quick ratio of 6.97.

Celadon Pharmaceuticals Company Profile

(Get Free Report)

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

Featured Stories

Receive News & Ratings for Celadon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celadon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.